Dr. Bruno Osterwalder is a board-certified hematologist and oncologist with a background of 15 years of academic and clinical practice in internal medicine, hematology and oncology (Swiss board certifications). He subsequently spent 18 years after in functions with increasing scientific and global managerial responsibilities in global drug development and strategic portfolio management at F. Hoffmann-Roche in the areas of hematology, oncology and renal and cancer anemia. After this, Dr. Osterwalder spent 6 years in global oncology and immuno-oncology drug development with a focus on early POC stages, translational medicine questions, Chinese and Japanese developments and strategic portfolio advice to top management in Merck Serono in Darmstadt, Germany. This resulted in a deep understanding of all modern drug development stages from research transition into humans up to global registrations and life cycle management with NCE’s and NBE’s including immunotherapeutics and vaccines. As member of Business Development teams, steering committees and advisory boards, Dr. Osterwalder is used to assessing and analyzing research and clinical programs and company portfolios, allowing him to build an extensive network with many biotech and pharma companies around the world. Interactions with regulatory authorities included the US, EU, Japan, Australia and Canada and had led to successful worldwide registrations for several oncology compounds. Presentations to various scientific, regulatory and public audiences were made at international conferences.
Since May 1st, 2015 Dr. Osterwalder has been serving as a consultant and board director to pharmaceutical companies covering strategic drug development aspects in oncology, hematology and immuno-oncology. Specific experience includes the transition from preclinical to clinical development and the combined development of companion diagnostics with therapeutic drugs in the context of targeted therapies and stratified medicine. Dr. Osterwalder is a member of professional societies such as ASCO, AACR, ASH, ECCO and ESMO.

Heinz Schwer, PhD, MBA, is currently the CEO of ViraTherapeutics, an Austrian-based biotechnology company developing immunotherapeutics for cancer treatment. Prior to joining ViraTherapeutics, Dr. Schwer served as CEO of therapeutic peptide developer, Lanthio Pharma B.V. from 2014-2017. Before his time at Lanthio, Dr. Schwer was Senior Director at MorphoSys AG from 2010 until 2014. In this period, he served as strategic technology advisor and head of “Innovation Capital”, the company’s corporate venture business. He was previously founder and CEO of Sloning BioTechnology GmbH, which was acquired by MorphoSys, where he managed the integration of the Slonomics® technology platform. Dr. Schwer did his postdoctoral fellowship training at Harvard Medical School, USA after having completed his PhD in clinical chemistry from the University of Regensburg, Germany. He also holds an MBA degree from Henley Management College, UK.